Wechselwirkungen · Torisel
Torisel 30 mg concentrate and solvent for solution for infusion · Abschnitt 4.5 · PDF-Seite 10
HOS-208978 · Präparat HOS-154221
There have been reports of increased blood levels of other mTOR inhibitors during concomitant use with cannabidiol. Co-administration of cannabidiol with another orally administered mTOR inhibitor in a healthy volunteer study led to an increase in exposure to the mTOR inhibitor of approximately 2.5- fold for both Cmax and AUC, due to inhibition of intestinal P-gp efflux by cannabidiol. Temsirolimus was demonstrated to be a substrate for P-gp in vitro. Caution should be used when cannabidiol and temsirolimus are co-administered, closely monitoring for side effects and adjusting the temsirolimus dose as needed (see sections 4.2 and 4 4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): cannabidiol (HOS-090609)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-03-03T15:46:00Z · SHA-256 f3c5550dfcb830d2de46566ba2243d0ebed5a8365e91770a67e6d6f36e348415 · Passage a37b091fa34ab805d918f8696d1756cdfc02c9a970e8356c2db69c7687af7a1e · Zeichen 2764–3407 im Abschnitt